FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3107054865> ?p ?o ?g. }

• W3107054865 endingPage "106252" @default.
• W3107054865 startingPage "106252" @default.
• W3107054865 abstract "• Despite successful antiretroviral therapy, patients with human immunodeficiency virus (HIV) could develop multi-class drug resistance (MDR) • Data about the prevalence of HIV-MDR are scanty and results are unclear • A significant decline in the prevalence of HIV-MDR over between 1998 and 2018 was observed • Nowadays, HIV-MDR still occurs, although at a lower rate • Management of patients infected by MDR viruses is a critical issue in HIV therapy Despite successful antiretroviral therapy (ART), patients infected with human immunodeficiency virus (HIV) can develop multi-class drug resistance (MDR). This retrospective study aimed to explore the prevalence of HIV-1 drug resistance over the past two decades by focusing on HIV-MDR and its predictors. ART-experienced patients with HIV with results from at least one plasma genotypic resistance test (GRT) from 1998 to 2018, from the Antiviral Response Cohort Analysis database, were included in this study. The temporal trend of resistance to any drug class was evaluated by considering all GRTs. Prevalence and predictors of HIV-MDR were analysed by consideration of cumulative GRTs. Among 15 628 isolates from 6802 patients, resistance to at least one drug class decreased sharply from 1998 to 2010 (1998–2001: 78%; 2008–2010: 59%; P <0.001) and then remained relatively constant at approximately 50% from 2011 to 2018, with the proportion of isolates with HIV-MDR also stable (approximately 9%). By evaluating factors associated with cumulative HIV-MDR, the following factors were found to be associated with increased risk of HIV-MDR on multi-variate analysis: male gender; sexual and vertical transmission; number of previous protease inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-NRTIs; previous exposure to integrase strand transfer inhibitors, enfuvirtide and maraviroc; and co-infection with hepatitis B virus. In contrast, a nadir CD4 cell count ≥200 cells/mm 3 , starting first-line ART in 2008 or later and co-infection with hepatitis C virus were associated with lower risk of HIV-MDR. In conclusion, this study revealed that HIV-1 drug resistance has been stable since 2011 despite its dramatic decrease over the past two decades. HIV-MDR is still present, although at a lower rate, suggesting the need for continuous surveillance and accurate management of ART-experienced patients with HIV." @default.
• W3107054865 created "2020-12-07" @default.
• W3107054865 creator A5002994994 @default.
• W3107054865 creator A5006029474 @default.
• W3107054865 creator A5016846891 @default.
• W3107054865 creator A5021259835 @default.
• W3107054865 creator A5023984688 @default.
• W3107054865 creator A5031864269 @default.
• W3107054865 creator A5049035721 @default.
• W3107054865 creator A5049928790 @default.
• W3107054865 creator A5052006950 @default.
• W3107054865 creator A5059232573 @default.
• W3107054865 creator A5060154255 @default.
• W3107054865 creator A5066309477 @default.
• W3107054865 creator A5066390359 @default.
• W3107054865 creator A5085061051 @default.
• W3107054865 creator A5089578403 @default.
• W3107054865 creator A5091290072 @default.
• W3107054865 date "2021-02-01" @default.
• W3107054865 modified "2023-10-03" @default.
• W3107054865 title "Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database" @default.
• W3107054865 cites W1497870368 @default.
• W3107054865 cites W1690495699 @default.
• W3107054865 cites W1967957254 @default.
• W3107054865 cites W1972799214 @default.
• W3107054865 cites W1981526509 @default.
• W3107054865 cites W2008137278 @default.
• W3107054865 cites W2012392023 @default.
• W3107054865 cites W2020780549 @default.
• W3107054865 cites W2024988708 @default.
• W3107054865 cites W2041510111 @default.
• W3107054865 cites W2046809024 @default.
• W3107054865 cites W2052536101 @default.
• W3107054865 cites W2062044789 @default.
• W3107054865 cites W2068674470 @default.
• W3107054865 cites W2077916906 @default.
• W3107054865 cites W2129294673 @default.
• W3107054865 cites W2134574624 @default.
• W3107054865 cites W2137795402 @default.
• W3107054865 cites W2145107025 @default.
• W3107054865 cites W2155192550 @default.
• W3107054865 cites W2167395385 @default.
• W3107054865 cites W2339873888 @default.
• W3107054865 cites W2346099372 @default.
• W3107054865 cites W2547674430 @default.
• W3107054865 cites W2614411843 @default.
• W3107054865 cites W2776721839 @default.
• W3107054865 cites W2884986477 @default.
• W3107054865 cites W2915372808 @default.
• W3107054865 cites W3002036436 @default.
• W3107054865 cites W3008245433 @default.
• W3107054865 doi "https://doi.org/10.1016/j.ijantimicag.2020.106252" @default.
• W3107054865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33259914" @default.
• W3107054865 hasPublicationYear "2021" @default.
• W3107054865 type Work @default.
• W3107054865 sameAs 3107054865 @default.
• W3107054865 citedByCount "8" @default.
• W3107054865 countsByYear W31070548652021 @default.
• W3107054865 countsByYear W31070548652022 @default.
• W3107054865 countsByYear W31070548652023 @default.
• W3107054865 crossrefType "journal-article" @default.
• W3107054865 hasAuthorship W3107054865A5002994994 @default.
• W3107054865 hasAuthorship W3107054865A5006029474 @default.
• W3107054865 hasAuthorship W3107054865A5016846891 @default.
• W3107054865 hasAuthorship W3107054865A5021259835 @default.
• W3107054865 hasAuthorship W3107054865A5023984688 @default.
• W3107054865 hasAuthorship W3107054865A5031864269 @default.
• W3107054865 hasAuthorship W3107054865A5049035721 @default.
• W3107054865 hasAuthorship W3107054865A5049928790 @default.
• W3107054865 hasAuthorship W3107054865A5052006950 @default.
• W3107054865 hasAuthorship W3107054865A5059232573 @default.
• W3107054865 hasAuthorship W3107054865A5060154255 @default.
• W3107054865 hasAuthorship W3107054865A5066309477 @default.
• W3107054865 hasAuthorship W3107054865A5066390359 @default.
• W3107054865 hasAuthorship W3107054865A5085061051 @default.
• W3107054865 hasAuthorship W3107054865A5089578403 @default.
• W3107054865 hasAuthorship W3107054865A5091290072 @default.
• W3107054865 hasBestOaLocation W31070548652 @default.
• W3107054865 hasConcept C114851261 @default.
• W3107054865 hasConcept C126322002 @default.
• W3107054865 hasConcept C133936738 @default.
• W3107054865 hasConcept C142462285 @default.
• W3107054865 hasConcept C167135981 @default.
• W3107054865 hasConcept C203014093 @default.
• W3107054865 hasConcept C2776452011 @default.
• W3107054865 hasConcept C2778176773 @default.
• W3107054865 hasConcept C2778451633 @default.
• W3107054865 hasConcept C2780035454 @default.
• W3107054865 hasConcept C2780727368 @default.
• W3107054865 hasConcept C2993143319 @default.
• W3107054865 hasConcept C3013748606 @default.
• W3107054865 hasConcept C41008148 @default.
• W3107054865 hasConcept C71924100 @default.
• W3107054865 hasConcept C72563966 @default.
• W3107054865 hasConcept C77088390 @default.
• W3107054865 hasConcept C86803240 @default.
• W3107054865 hasConcept C89423630 @default.
• W3107054865 hasConcept C98274493 @default.

• next